New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 14, 2013
06:09 EDTUTHRUnited Therapeutics reports FDA acceptance of oral Treprostinil NDA reacceptance
United Therapeutics announced that the U.S. Food and Drug Administration has acknowledged the resubmission of the new drug application for treprostinil diolamine extended release tablets for the treatment of pulmonary arterial hypertension. The FDA classified the resubmission as a complete, class 1 response to FDA's October 23, 2012 complete response letter and the FDA set a user fee goal date of March 31, 2013.
News For UTHR From The Last 14 Days
Check below for free stories on UTHR the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 29, 2014
16:21 EDTUTHROn The Fly: Closing Wrap
Subscribe for More Information
13:05 EDTUTHRUnited Therapeutics price target raised to $141 from $133 at Wedbush
Subscribe for More Information
12:53 EDTUTHRCourt ruling in Remodulin patent case favors United Therapeutics
Subscribe for More Information
12:49 EDTUTHRStocks with increasing volume options volume
Stocks with increasing volume options volume: OXY HD RSH UTHR IRF TTWO CONN
12:18 EDTUTHROn The Fly: Midday Wrap
Subscribe for More Information
11:07 EDTUTHRHigh option volume stocks
Subscribe for More Information
10:51 EDTUTHRUnited Therapeutics jumps after court rules generic will infringe
United Therapeutics (UTHR) alleged patent infringement against Sandoz, a unit of Novartis (NVS), related to the latter's filing for approval of a generic version of United Therapeutics' remodulin drug. A New Jersey court ruled today that Sandoz's proposed ANDA product will infringe the claims of UTC's '117 patent, according to a court filing. Following the court ruling, shares of United Therapeutics are up 15% to $105.39 in morning trading.
August 18, 2014
11:41 EDTUTHRCubist rises after report sparks takeover interest speculation
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use